Initial clinical, morphologic, and biologic characteristics of the 124 patients with MZL included in this analysis
| . | No. Patients . | Patients Not Evaluable . | Spleen Subtype . | Leukemic Subtype . | Nodal Subtype . | Disseminated Subtype . | P Value . |
|---|---|---|---|---|---|---|---|
| N | 124 | 59 | 8 | 37 | 20 | ||
| Sex: Male | 57 (46%) | — | 26 (44%) | 3 (37.5%) | 16 (43%) | 12 (60%) | |
| Age >60 y | 67 (54%) | — | 37 (63%) | 7 (87.5%) | 13 (35%) | 10 (50%) | .013 |
| Poor performance status | 21 (18%) | 9 | 10 (17%) | 0 | 4 (12.5%) | 7 (39%) | |
| B symptoms | 26 (21%) | — | 15 (25%) | 0 | 5 (13.5%) | 6 (30%) | |
| Stage III or IV | 106 (86%) | — | 54 (91.5%) | 8 (100%) | 25 (68%) | 19 (95%) | .003 |
| Peripheral lymph nodes | 55 (44%) | — | 0 | 0 | 35 (95%) | 20 (100%) | |
| Abdominal/thoracic lymph nodes | 49 (48%) | — | 20 (34%) | 0 | 18 (49%) | 11 (55%) | <.05 |
| Bone marrow + | 90 (73%) | — | 51 (86%) | 8 (100%) | 15 (43%) | 16 (80%) | <.0001 |
| Splenomegaly | 79 (64%) | — | 59 (100%) | 0 | 0 | 19 (95%) | |
| Liver involvement | 20 (16%) | — | 14 (24%) | 0 | 2 (5%) | 4 (20%) | |
| Pleura localization | 14 (11%) | — | 3 (5%) | 2 (25%) | 1 (3%) | 8 (40%) | <.0001 |
| Head and neck localization | 4 (3%) | — | 0 | 0 | 4 (11%) | 0 | <.05 |
| Extranodal sites >1 | 68 (56%) | 2 | 40 (68%) | 5 (62.5%) | 9 (25%) | 14 (74%) | .0002 |
| Bulky tumor | 45 (39%) | 10 | 28 (50%) | 0 | 6 (17%) | 11 (65%) | .0004 |
| Hemoglobin <12 g/dL | 54 (52%) | 20 | 34 (64%) | 1 (14%) | 8 (31%) | 11 (61%) | <.01 |
| Blood involvement | 53 (43%) | 2 | 34 (57%) | 6 (75%) | 4 (11%) | 9 (45%) | <.0001 |
| Serum albumin <35 g/L | 21 (25%) | 39 | 12 (25.5%) | 2 (40%) | 2 (10%) | 5 (38.5%) | |
| LDH > normal values | 43 (43%) | 24 | 20 (43%) | 1 (20%) | 12 (40%) | 10 (56%) | |
| β2-microglobulin >3 mg/L | 52 (59%) | 36 | 30 (65%) | 3 (75%) | 8 (33%) | 11 (79%) | .02 |
| M component | 19 (19%) | 22 | 14 (24%) | 0 | 3 (8%) | 2 (12%) | |
| International Prognostic Index | 26 | <.0001 | |||||
| Low risk | 15 (13%) | 5 (10%) | 1 (20%) | 9 (31%) | 0 | ||
| Low-intermediate risk | 33 (34%) | 15 (32%) | 4 (80%) | 8 (28%) | 5 (29.5%) | ||
| High-intermediate risk | 33 (34%) | 20 (43%) | 0 | 7 (24%) | 5 (29.5%) | ||
| High risk | 19 (19%) | 7 (15%) | 0 | 5 (17%) | 7 (41%) |
| . | No. Patients . | Patients Not Evaluable . | Spleen Subtype . | Leukemic Subtype . | Nodal Subtype . | Disseminated Subtype . | P Value . |
|---|---|---|---|---|---|---|---|
| N | 124 | 59 | 8 | 37 | 20 | ||
| Sex: Male | 57 (46%) | — | 26 (44%) | 3 (37.5%) | 16 (43%) | 12 (60%) | |
| Age >60 y | 67 (54%) | — | 37 (63%) | 7 (87.5%) | 13 (35%) | 10 (50%) | .013 |
| Poor performance status | 21 (18%) | 9 | 10 (17%) | 0 | 4 (12.5%) | 7 (39%) | |
| B symptoms | 26 (21%) | — | 15 (25%) | 0 | 5 (13.5%) | 6 (30%) | |
| Stage III or IV | 106 (86%) | — | 54 (91.5%) | 8 (100%) | 25 (68%) | 19 (95%) | .003 |
| Peripheral lymph nodes | 55 (44%) | — | 0 | 0 | 35 (95%) | 20 (100%) | |
| Abdominal/thoracic lymph nodes | 49 (48%) | — | 20 (34%) | 0 | 18 (49%) | 11 (55%) | <.05 |
| Bone marrow + | 90 (73%) | — | 51 (86%) | 8 (100%) | 15 (43%) | 16 (80%) | <.0001 |
| Splenomegaly | 79 (64%) | — | 59 (100%) | 0 | 0 | 19 (95%) | |
| Liver involvement | 20 (16%) | — | 14 (24%) | 0 | 2 (5%) | 4 (20%) | |
| Pleura localization | 14 (11%) | — | 3 (5%) | 2 (25%) | 1 (3%) | 8 (40%) | <.0001 |
| Head and neck localization | 4 (3%) | — | 0 | 0 | 4 (11%) | 0 | <.05 |
| Extranodal sites >1 | 68 (56%) | 2 | 40 (68%) | 5 (62.5%) | 9 (25%) | 14 (74%) | .0002 |
| Bulky tumor | 45 (39%) | 10 | 28 (50%) | 0 | 6 (17%) | 11 (65%) | .0004 |
| Hemoglobin <12 g/dL | 54 (52%) | 20 | 34 (64%) | 1 (14%) | 8 (31%) | 11 (61%) | <.01 |
| Blood involvement | 53 (43%) | 2 | 34 (57%) | 6 (75%) | 4 (11%) | 9 (45%) | <.0001 |
| Serum albumin <35 g/L | 21 (25%) | 39 | 12 (25.5%) | 2 (40%) | 2 (10%) | 5 (38.5%) | |
| LDH > normal values | 43 (43%) | 24 | 20 (43%) | 1 (20%) | 12 (40%) | 10 (56%) | |
| β2-microglobulin >3 mg/L | 52 (59%) | 36 | 30 (65%) | 3 (75%) | 8 (33%) | 11 (79%) | .02 |
| M component | 19 (19%) | 22 | 14 (24%) | 0 | 3 (8%) | 2 (12%) | |
| International Prognostic Index | 26 | <.0001 | |||||
| Low risk | 15 (13%) | 5 (10%) | 1 (20%) | 9 (31%) | 0 | ||
| Low-intermediate risk | 33 (34%) | 15 (32%) | 4 (80%) | 8 (28%) | 5 (29.5%) | ||
| High-intermediate risk | 33 (34%) | 20 (43%) | 0 | 7 (24%) | 5 (29.5%) | ||
| High risk | 19 (19%) | 7 (15%) | 0 | 5 (17%) | 7 (41%) |
LDH = lactic dehydrogenase; MZL = marginal zone B-cell lymphoma.